ANATOMICAL BENEFIT FROM RANIBIZUMAB TREATMENT OF PREDOMINANTLY CLASSIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE 2-YEAR ANCHOR STUDY